Cellectis (CLLS) Free Cash Flow (2015 - 2026)
Cellectis (CLLS) posted quarterly Free Cash Flow of -$15.1 million for Q1 2026, up 9.66% year-over-year from -$13.8 million in Q1 2025, and down 3.73% quarter-over-quarter from -$14.6 million in Q4 2025.
Cellectis (CLLS) Free Cash Flow (2015 - 2026) Analysis & Trends
Cellectis' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$15.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 9.66% year-over-year to -$15.1 million; the TTM figure through Mar 2026 stood at -$40.1 million (down 250.13% YoY), while the FY2025 annual figure was -$41.8 million, down 304.65% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$15.1 million, down from -$14.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $53.2 million in Q2 2024, with the low at -$36.0 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$15.1 million (2026), against an average of -$9.0 million.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 239.39% in 2022, then surged 771.05% in 2023.
- Cellectis' Free Cash Flow stood at -$5.6 million in 2022, then soared by 771.05% to $37.8 million in 2023, then tumbled by 112.32% to -$4.7 million in 2024, then tumbled by 213.12% to -$14.6 million in 2025, then dropped by 3.73% to -$15.1 million in 2026.
- Business Quant data shows CLLS's Free Cash Flow at -$15.1 million in Q1 2026, -$14.6 million in Q4 2025, and -$390000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -15.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.15 Mn |
| Mar 31, 2026 | -15.15 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | -390,000.00 |
| Sep 30, 2025 | -390,000.00 |
| Jun 30, 2025 | -10.01 Mn |
| Jun 30, 2025 | -10.01 Mn |
| Mar 31, 2025 | -16.77 Mn |
| Mar 31, 2025 | -16.77 Mn |
| Dec 31, 2024 | -4.66 Mn |
| Dec 31, 2024 | -4.66 Mn |
| Sep 30, 2024 | -5.05 Mn |
| Sep 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | 53.22 Mn |
| Jun 30, 2024 | 53.22 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Mar 31, 2024 | -23.10 Mn |
| Dec 31, 2023 | 37.85 Mn |
| Dec 31, 2023 | 37.85 Mn |